Company / Cost of Revenue
Pacira BioSciences, Inc. Cost of Revenue History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$149.7M
FY2025
5-year range
$106.7M / $199.3M
FY2021-FY2025
Trend
-12.1%
vs FY2024
Sector context
#41 of 85
Health Care
What the data says
At $150M, Pacira BioSciences, Inc.'s cost of revenue ranks #45 of 85 in the Health Care sector. Cost of Revenue has declined for 3 consecutive years, from $199M in FY2022 to $150M in FY2025.
Based on SEC 10-K filings.
$150M in FY2025 with a 5-year CAGR of +11.5%.
Improved from $185M to $150M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -9.1%
- 5-Year CAGR
- +11.5%
- 10-Year CAGR
- -
Sector benchmark
#45 of 85 in Health CareTop 52% of 85This company $149.7M Sector average $2.0B
▼
-92.4% below sector average
Key checks
Key Insights
- Pacira BioSciences, Inc.'s cost of revenue has declined for 3 consecutive years.
- 5-year CAGR of +11.5%, indicating consistent growth.
- In FY2025, cost of revenue decreased 12.1% year-over-year.
- Ranks #41 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Negative profit margin: -14.8%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $149.7M | -12.1% |
| FY2024 | $170.4M | -7.7% |
| FY2023 | $184.7M | -7.3% |
| FY2022 | $199.3M | +86.8% |
| FY2021 | $106.7M | +22.9% |
| FY2020 | $86.8M | -1.2% |
| FY2019 | $87.9M | -20.2% |
| FY2018 | $110.1M | +53.3% |
| FY2017 | $71.8M | -34.8% |
| FY2016 | $110.1M | +53.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026